{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:03:34Z","timestamp":1758672214247,"version":"3.44.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,11,20]],"date-time":"2014-11-20T00:00:00Z","timestamp":1416441600000},"content-version":"vor","delay-in-days":1419,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"NIAID, NIH","award":["R44-AI-048990"],"award-info":[{"award-number":["R44-AI-048990"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.virol.2010.09.026","type":"journal-article","created":{"date-parts":[[2010,11,11]],"date-time":"2010-11-11T04:21:03Z","timestamp":1289449263000},"page":"308-318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Mutational pathways and genetic barriers to CXCR4-mediated entry by human immunodeficiency virus type 1"],"prefix":"10.1016","volume":"409","author":[{"given":"Wei","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arne","family":"Frantzell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Toma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Signe","family":"Fransen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeannette M.","family":"Whitcomb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Stawiski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos J.","family":"Petropoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2010.09.026_bb0005","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1146\/annurev.immunol.17.1.657","article-title":"Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease","volume":"17","author":"Berger","year":"1999","journal-title":"Annu. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.virol.2010.09.026_bb0010","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1086\/431519","article-title":"Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals","volume":"192","author":"Brumme","year":"2005","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.virol.2010.09.026_bb0015","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/aid.2006.0130","article-title":"Structural basis for coreceptor selectivity by the HIV type 1 V3 loop","volume":"23","author":"Cardozo","year":"2007","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"12","key":"10.1016\/j.virol.2010.09.026_bb0020","doi-asserted-by":"crossref","first-page":"9055","DOI":"10.1128\/jvi.70.12.9055-9059.1996","article-title":"Mapping of independent V3 envelope determinants of human immunodeficiency virus type 1 macrophage tropism and syncytium formation in lymphocytes","volume":"70","author":"Chesebro","year":"1996","journal-title":"J. Virol."},{"year":"2006","series-title":"2nd International Workshop on Targeting HIV Entry, Boston, MA","author":"Coakley","key":"10.1016\/j.virol.2010.09.026_bb0025"},{"issue":"11","key":"10.1016\/j.virol.2010.09.026_bb0030","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/nm1196-1244","article-title":"The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection","volume":"2","author":"Cocchi","year":"1996","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.virol.2010.09.026_bb0035","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1084\/jem.185.4.621","article-title":"Change in coreceptor use correlates with disease progression in HIV-1-infected individuals","volume":"185","author":"Connor","year":"1997","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.virol.2010.09.026_bb0040","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1086\/650697","article-title":"Maraviroc versus efavirenz, both in combination with zidovudine\u2013lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection","volume":"201","author":"Cooper","year":"2010","journal-title":"J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.virol.2010.09.026_bb0045","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1086\/520650","article-title":"Baseline HIV type 1 coreceptor tropism predicts disease progression","volume":"45","author":"Daar","year":"2007","journal-title":"Clin. Infect. Dis."},{"issue":"11","key":"10.1016\/j.virol.2010.09.026_bb0050","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1128\/jvi.66.11.6777-6780.1992","article-title":"Minimal requirements for the human immunodeficiency virus type 1V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution","volume":"66","author":"De Jong","year":"1992","journal-title":"J. Virol."},{"year":"2004","series-title":"44th Interscience Conference on Antimicrobial Agents and Chemotherapeutics, Washington, DC","author":"Demarest","key":"10.1016\/j.virol.2010.09.026_bb0055"},{"issue":"6584","key":"10.1016\/j.virol.2010.09.026_bb0060","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/381661a0","article-title":"Identification of a major co-receptor for primary isolates of HIV-1","volume":"381","author":"Deng","year":"1996","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.virol.2010.09.026_bb0065","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/QAD.0b013e32810fd72e","article-title":"Antiretroviral drug resistance, HIV-1 tropism, and HIV-1 subtype among men who have sex with men with recent HIV-1 infection","volume":"21","author":"Eshleman","year":"2007","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.virol.2010.09.026_bb0070","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1128\/jvi.66.5.3183-3187.1992","article-title":"Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule","volume":"66","author":"Fouchier","year":"1992","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/j.virol.2010.09.026_bb0075","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1128\/AAC.01226-07","article-title":"Suppression of dualtropic human immunodeficiency virus type 1 by the CXCR4 antagonist AMD3100 is associated with efficiency of CXCR4 use and baseline virus composition","volume":"52","author":"Fransen","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.virol.2010.09.026_bb0080","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1086\/518797","article-title":"Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211","volume":"196","author":"Gulick","year":"2007","journal-title":"J. Infect. Dis."},{"issue":"14","key":"10.1016\/j.virol.2010.09.026_bb0085","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa0803152","article-title":"Maraviroc for previously treated patients with R5 HIV-1 infection","volume":"359","author":"Gulick","year":"2008","journal-title":"N Engl J. Med."},{"issue":"2","key":"10.1016\/j.virol.2010.09.026_bb0090","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1097\/01.qai.0000137371.80695.ef","article-title":"Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection","volume":"37","author":"Hendrix","year":"2004","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"1","key":"10.1016\/j.virol.2010.09.026_bb0095","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/096876899294760","article-title":"HIV-1 envelope determinants for cell tropism and chemokine receptor use","volume":"16","author":"Hoffman","year":"1999","journal-title":"Mol. Membr. Biol."},{"issue":"15","key":"10.1016\/j.virol.2010.09.026_bb0100","doi-asserted-by":"crossref","first-page":"7885","DOI":"10.1128\/JVI.00218-07","article-title":"Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations","volume":"81","author":"Huang","year":"2007","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.virol.2010.09.026_bb0105","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.1128\/JVI.02676-07","article-title":"Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein","volume":"82","author":"Huang","year":"2008","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.virol.2010.09.026_bb0110","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1089\/aid.2008.0252","article-title":"Characterization of human immunodeficiency virus type 1 populations containing CXCR4-using variants from recently infected individuals","volume":"25","author":"Huang","year":"2009","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"10","key":"10.1016\/j.virol.2010.09.026_bb0115","doi-asserted-by":"crossref","first-page":"8216","DOI":"10.1128\/JVI.73.10.8216-8226.1999","article-title":"Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization","volume":"73","author":"Hung","year":"1999","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/j.virol.2010.09.026_bb0120","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/507312","article-title":"Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia","volume":"194","author":"Hunt","year":"2006","journal-title":"J. Infect. Dis."},{"issue":"5015","key":"10.1016\/j.virol.2010.09.026_bb0125","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1126\/science.1905842","article-title":"Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1","volume":"253","author":"Hwang","year":"1991","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.virol.2010.09.026_bb0130","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1128\/AAC.01293-09","article-title":"Blockade of X4-tropic HIV-1 cellular entry by GSK812397, a potent noncompetitive CXCR4 receptor antagonist","volume":"54","author":"Jenkinson","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"24","key":"10.1016\/j.virol.2010.09.026_bb0135","doi-asserted-by":"crossref","first-page":"13376","DOI":"10.1128\/JVI.77.24.13376-13388.2003","article-title":"Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences","volume":"77","author":"Jensen","year":"2003","journal-title":"J. Virol."},{"issue":"9","key":"10.1016\/j.virol.2010.09.026_bb0140","doi-asserted-by":"crossref","first-page":"681","DOI":"10.7326\/0003-4819-118-9-199305010-00004","article-title":"Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS","volume":"118","author":"Koot","year":"1993","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.virol.2010.09.026_bb0145","first-page":"S65","article-title":"CXCR4-using virus detected in patients receiving maraviroc in the phase III studies MOTIVATE 1 and 2 originates from a pre-existing minority of CXCR4-using virus","volume":"12","author":"Lewis","year":"2007","journal-title":"Antivir. Ther."},{"issue":"2","key":"10.1016\/j.virol.2010.09.026_bb0150","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1089\/aid.2007.0140","article-title":"CD4-dependent characteristics of coreceptor use and HIV type 1 V3 sequence in a large population of therapy-naive individuals","volume":"24","author":"Low","year":"2008","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"9464","key":"10.1016\/j.virol.2010.09.026_bb0155","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0140-6736(05)71139-9","article-title":"Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report","volume":"365","author":"Markowitz","year":"2005","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.virol.2010.09.026_bb0160","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/QAD.0b013e3280117053","article-title":"Virological characterization of an infection with a dual-tropic, multidrug-resistant HIV-1 and further evolution on antiretroviral therapy","volume":"21","author":"Masquelier","year":"2007","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.virol.2010.09.026_bb0165","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1086\/504693","article-title":"HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response","volume":"194","author":"Melby","year":"2006","journal-title":"J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.virol.2010.09.026_bb0170","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1128\/JVI.73.5.3544-3550.1999","article-title":"Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants","volume":"73","author":"Mosier","year":"1999","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.virol.2010.09.026_bb0175","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1086\/428096","article-title":"Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection","volume":"191","author":"Moyle","year":"2005","journal-title":"J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.virol.2010.09.026_bb0180","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1086\/597097","article-title":"Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1","volume":"48","author":"Moyle","year":"2009","journal-title":"Clin. Infect. Dis."},{"issue":"7","key":"10.1016\/j.virol.2010.09.026_bb0185","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1128\/AAC.01727-08","article-title":"The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100","volume":"53","author":"Murakami","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6296","key":"10.1016\/j.virol.2010.09.026_bb0190","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/348069a0","article-title":"HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain","volume":"348","author":"O'Brien","year":"1990","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.virol.2010.09.026_bb0195","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1128\/JVI.80.2.750-758.2006","article-title":"Human immunodeficiency virus type 1 coreceptor switching: V1\/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations","volume":"80","author":"Pastore","year":"2006","journal-title":"J. Virol."},{"issue":"16","key":"10.1016\/j.virol.2010.09.026_bb0200","doi-asserted-by":"crossref","first-page":"13433","DOI":"10.1074\/jbc.M009779200","article-title":"N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization","volume":"276","author":"Pollakis","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.virol.2010.09.026_bb0205","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1006\/viro.2001.1087","article-title":"Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks","volume":"288","author":"Resch","year":"2001","journal-title":"Virology"},{"issue":"5","key":"10.1016\/j.virol.2010.09.026_bb0210","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/infdis\/169.5.968","article-title":"The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression","volume":"169","author":"Richman","year":"1994","journal-title":"J. Infect. Dis."},{"issue":"11","key":"10.1016\/j.virol.2010.09.026_bb0215","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1086\/598965","article-title":"A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1","volume":"199","author":"Saag","year":"2009","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.virol.2010.09.026_bb0220","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1006\/jmbi.1993.1626","article-title":"Comparative protein modelling by satisfaction of spatial restraints","volume":"234","author":"Sali","year":"1993","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.virol.2010.09.026_bb0225","first-page":"404","article-title":"The \u201cmegaprimer\u201d method of site-directed mutagenesis","volume":"8","author":"Sarkar","year":"1990","journal-title":"Biotechniques"},{"issue":"3","key":"10.1016\/j.virol.2010.09.026_bb0230","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1128\/jvi.66.3.1354-1360.1992","article-title":"Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population","volume":"66","author":"Schuitemaker","year":"1992","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.virol.2010.09.026_bb0235","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1086\/591623","article-title":"Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the multicenter AIDS cohort study","volume":"198","author":"Shepherd","year":"2008","journal-title":"J. Infect. Dis."},{"issue":"6305","key":"10.1016\/j.virol.2010.09.026_bb0240","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/349167a0","article-title":"Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene","volume":"349","author":"Shioda","year":"1991","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.virol.2010.09.026_bb0245","doi-asserted-by":"crossref","first-page":"7136","DOI":"10.1128\/jvi.71.9.7136-7139.1997","article-title":"Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop","volume":"71","author":"Speck","year":"1997","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.virol.2010.09.026_bb0250","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1086\/648090","article-title":"Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211","volume":"200","author":"Su","year":"2009","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.virol.2010.09.026_bb0255","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1086\/650342","article-title":"Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial","volume":"201","author":"Suleiman","year":"2010","journal-title":"J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.virol.2010.09.026_bb0260","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1128\/jvi.63.5.2118-2125.1989","article-title":"Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates","volume":"63","author":"Tersmette","year":"1989","journal-title":"J. Virol."},{"issue":"6605","key":"10.1016\/j.virol.2010.09.026_bb0265","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/384184a0","article-title":"CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5","volume":"384","author":"Trkola","year":"1996","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.virol.2010.09.026_bb0270","doi-asserted-by":"crossref","first-page":"9006","DOI":"10.1128\/JVI.79.14.9006-9018.2005","article-title":"Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression","volume":"79","author":"Troyer","year":"2005","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.virol.2010.09.026_bb0275","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1006\/viro.1996.0158","article-title":"Identification of the envelope V3 loop as a determinant of a CD4-negative neuronal cell tropism for HIV-1","volume":"217","author":"Trujillo","year":"1996","journal-title":"Virology"},{"issue":"5","key":"10.1016\/j.virol.2010.09.026_bb0280","doi-asserted-by":"crossref","first-page":"e5683","DOI":"10.1371\/journal.pone.0005683","article-title":"Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo","volume":"4","author":"Tsibris","year":"2009","journal-title":"PLoS ONE"},{"issue":"10","key":"10.1016\/j.virol.2010.09.026_bb0285","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1128\/JVI.80.10.4909-4920.2006","article-title":"Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir","volume":"80","author":"Westby","year":"2006","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.virol.2010.09.026_bb0290","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1128\/jvi.66.4.2577-2582.1992","article-title":"Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo","volume":"66","author":"Westervelt","year":"1992","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.virol.2010.09.026_bb0295","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1128\/AAC.00853-06","article-title":"Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism","volume":"51","author":"Whitcomb","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.virol.2010.09.026_bb0300","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1086\/511035","article-title":"HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211","volume":"44","author":"Wilkin","year":"2007","journal-title":"Clin. Infect. Dis."},{"issue":"6605","key":"10.1016\/j.virol.2010.09.026_bb0305","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/384179a0","article-title":"CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5","volume":"384","author":"Wu","year":"1996","journal-title":"Nature"}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682210006148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682210006148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:10:49Z","timestamp":1758586249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682210006148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0042682210006148"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2010.09.026","relation":{},"ISSN":["0042-6822"],"issn-type":[{"type":"print","value":"0042-6822"}],"subject":[],"published":{"date-parts":[[2011,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mutational pathways and genetic barriers to CXCR4-mediated entry by human immunodeficiency virus type 1","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2010.09.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}